Terns Pharmaceuticals Inc
F:430
Terns Pharmaceuticals Inc
F:430
Price:
45.07
EUR
Market Closed
Market Cap:
€2.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Terns Pharmaceuticals Inc
F:430
|
US |
|
Genfit SA
OTC:GNFTY
|
FR |
|
D
|
Dave & Buster's Entertainment Inc
F:9DB
|
US |
|
S
|
Sedlmayr Grund und Immobilien AG
XMUN:SPB
|
DE |
|
M
|
Minesto AB
XMUN:7MN
|
SE |
|
C
|
Carlisle Companies Inc
XMUN:CLE
|
US |
|
A
|
Advanced Micro Devices Inc
MIL:1AMD
|
US |
|
U
|
UBE Corp
XMUN:UBE
|
JP |
|
H
|
Hugo Boss AG
XMUN:BOSS
|
DE |
|
D
|
Deutsche EuroShop AG
XMUN:DEQ
|
DE |
|
Pulmatrix Inc
F:2PU
|
US |
|
C
|
Creative Technology Ltd
XMUN:CTL
|
SG |
|
G
|
Gazprom Neft' PAO
F:SCF
|
RU |
|
T
|
Technicolor Creative Studios SA
PAR:TCHCS
|
FR |
|
F
|
Fluor Corp
XMUN:FLU
|
US |
|
C
|
Clearside Biomedical Inc
XMUN:CLM
|
US |
|
B
|
Buffalo Coal Corp
XTSX:BUF
|
ZA |
|
C
|
Commercial Metals Co
SWB:CMS
|
US |
|
S
|
Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
|
SE |
|
C
|
Commercial Metals Co
F:CMS
|
US |
|
China Resources Cement Holdings Ltd
F:C44
|
HK |
Wall St Price Targets
Price Targets Summary
Terns Pharmaceuticals Inc
Terns Pharmaceuticals Inc
There are no price targets for Terns Pharmaceuticals Inc.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Terns Pharmaceuticals Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is Terns Pharmaceuticals Inc's stock price target?
Not Available
Terns Pharmaceuticals Inc does not have any price targets made by Wall Street professionals.
